- Home
- EPAC vs NVCR Comparison
EPAC vs NVCR Comparison
Compare EPAC & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPAC
- NVCR
- Stock Information
- Founded
- EPAC 1910
- NVCR 2000
- Country
- EPAC United States
- NVCR Jersey
- Employees
- EPAC N/A
- NVCR N/A
- Industry
- EPAC Industrial Machinery/Components
- NVCR Medical/Dental Instruments
- Sector
- EPAC Technology
- NVCR Health Care
- Exchange
- EPAC Nasdaq
- NVCR Nasdaq
- Market Cap
- EPAC 2.4B
- NVCR 1.8B
- IPO Year
- EPAC N/A
- NVCR 2015
- Fundamental
- Price
- EPAC $44.59
- NVCR $17.49
- Analyst Decision
- EPAC Strong Buy
- NVCR Buy
- Analyst Count
- EPAC 1
- NVCR 5
- Target Price
- EPAC $35.00
- NVCR $26.60
- AVG Volume (30 Days)
- EPAC 388.1K
- NVCR 1.3M
- Earning Date
- EPAC 10-15-2024
- NVCR 10-30-2024
- Dividend Yield
- EPAC 0.09%
- NVCR N/A
- EPS Growth
- EPAC 91.76
- NVCR N/A
- EPS
- EPAC 1.56
- NVCR N/A
- Revenue
- EPAC $589,510,000.00
- NVCR $549,964,000.00
- Revenue This Year
- EPAC $10.55
- NVCR $16.23
- Revenue Next Year
- EPAC $5.46
- NVCR $6.09
- P/E Ratio
- EPAC $28.46
- NVCR N/A
- Revenue Growth
- EPAC N/A
- NVCR 8.33
- 52 Week Low
- EPAC $27.06
- NVCR $10.87
- 52 Week High
- EPAC $45.17
- NVCR $24.74
- Technical
- Relative Strength Index (RSI)
- EPAC 63.60
- NVCR 43.24
- Support Level
- EPAC $44.07
- NVCR $15.61
- Resistance Level
- EPAC $45.17
- NVCR $17.31
- Average True Range (ATR)
- EPAC 1.20
- NVCR 1.29
- MACD
- EPAC 0.03
- NVCR 0.05
- Stochastic Oscillator
- EPAC 91.78
- NVCR 11.59
About EPAC Enerpac Tool Group Corp.
Enerpac Tool Group, previously known as Actuant, provides high-precision tools, controlled-force products, and solutions for precise heavy lifting. The company operates through two segments: industrial tools and services and other. It categorizes its revenue into two parts: product sales and services, which include manpower services and rentals. Product sales is the largest contributor to the company's total revenue. Geographically, the company operates in the United States, Asia, Australia, Europe, Middle East, and other areas. The U.S. makes up the largest contribution to the company's total revenue.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.